Mereo BioPharma Group plc
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Operating Activities | ||||
| Net Income | $-41.9M | $-43.3M | $-29.5M | $-42.2M |
| Depreciation & Amortization | — | — | — | — |
| Depreciation | $157.0K | $143.0K | $171.0K | $181.0K |
| Amortization | $465.0K | $438.0K | $395.0K | $0 |
| Stock-Based Compensation | $7.6M | $7.4M | $4.9M | $4.8M |
| Net Cash from Operating Activities | $-31.0M | $-32.8M | $-21.1M | $-48.8M |
| Investing Activities | ||||
| Capital Expenditures | $20.0K | $0 | $0 | $13.0K |
| Business Acquisitions | — | — | — | — |
| Net Cash from Investing Activities | $-20.0K | $-699.0K | $-419.0K | $2.0M |
| Financing Activities | ||||
| Dividends Paid | — | — | — | — |
| Stock Repurchases | — | — | — | — |
| Net Cash from Financing Activities | $327.0K | $46.1M | $8.0M | $200.0K |
| Net Change in Cash | — | $12.4M | $-10.8M | — |
| Free Cash Flow | $-31.0M | $-32.8M | $-21.1M | $-48.8M |